Hepatic and systemic effects of rosuvastatin on an experimental model of bile duct ligation in rats

Journal of Physiology and Pharmacology

Volumn 63, Issue 5, 2012, Pages 483-496

  Olteanu, D ^a   Nagy, A ^b   Dudea, M ^a   Filip, A ^a   Muresan, A ^a   Catoi, C ^b   Mircea, P A ^a   Clichici, S ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

Author keywords

Bile duct ligation; Cholestasis; Fibrosis; Inflammation; Nuclear factor kappa B; Oxidative stress; Rosuvastatin; Tumor necrosis factor receptor 2

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ROSUVASTATIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CHOLESTASIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER PARENCHYMA; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TREATMENT DURATION;

ACTINS; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BILE DUCTS; BRAIN; CHOLESTASIS; DISEASE MODELS, ANIMAL; FEMALE; FLUOROBENZENES; GAMMA-GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; LIGATION; LIVER; MALONDIALDEHYDE; NF-KAPPA B; OXIDATIVE STRESS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN CARBONYLATION; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84870596570     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Tomur A, Kanter M, Gurel A, Erboga M. The efficiency of CAPE on retardation of hepatic fibrosis in biliary obstructed rats. J Mol Histol 2011; 42: 451-458.
2. Anan A, Baskin-Bey ES, Isomoto H. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Am J Physiol Gastrointest Liver Physiol 2006; 291: G709-G716.
3. Forbes SJ, Parola M. Liver fibrogenic cells. Best Pract Res Clin Gastroenterol 2011; 25: 207-217.
4. Olteanu D, Filip A, Muresan A, et al. The effects of chitosan and low dose dexamethasone on extrahepatic cholestasis after bile duct ligation in Wistar rats Acta Physiol Hung 2012; 99: 61-73.
5. Lotkova H, Stankova P, Rousar T, et al. Deteriorating effect of fluvastatin on the cholestatic liver injury induced by bile duct ligation in rats. Gen Physiol Biophys 2011; 30: 66-74.
6. Dold S, Laschke MW, Lavasani S, Menger MD, Jeppsson, Thorlacius H. Simvastatin protects against cholestasis-induced liver injury. Br J Pharmacol 2009; 156: 466-474.
7. Gianella A, Nobili E, Abbate M, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 2007; 170: 1165-1177.
8. Oberti F, Pilette C, Rifflet H, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997; 26: 1363-1371.
9. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53: 702-712.
10. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy volunteers. Clin Ther 2003; 25: 2822-2835.
11. Awad AS, Kamel R. Effect of rosuvastatin on cholestasis-induced hepatic injury in rat. Livers J Biochem Mol Toxicol 2010; 24: 89-94.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
13. Conti M, Moran PC, Levillain P. Improved fluorimetric determination of malondialdehyde. Clin Chem 1991; 37: 1273-1275.
14. Reznick AZ, Packer L. Oxidative damage to proteins spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233: 357-363.
15. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233: 380-384.
16. Floreani M, Petrone M, Debetto P, Palatini P. A comparison between different methods for the determination of reduced and oxidized glutathione in mammalian tissues. Free Radic Res 1997; 26: 449-455.
17. Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem 1978; 24: 58-73.
18. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
19. Tabaran F, Catoi C, Clichici S, et al. Immunohistochemical quantification of the tumor necrosis factor (TNF) receptor II expression in the hepatic tissue after systemic administration of the DNA-SWCNT. Bull USAMV 2011; 68: 370-375.
20. Kuver R. Effects of statins on cholestasis: good, bad or indifferent? J Gastroenterol Hepatol 2011; 26: 1544-1551.
21. Lichtenberger LM, Phan T, Okabe S. Aspirin's ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol 2011; 62: 491-496.
22. Petrovic I, Dobric I, Drmic D, et al. BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure. J Physiol Pharmacol 2011; 62: 527-534.
23. Kolouchova G, Brcakova E, Hirsova P, et al. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. J Gastroenterol. Hepatol 2011; 26: 1544-1551.
24. Dirlik M, Canbaz H, Dusmez A, et al. The monitoring of progress in apoptosis of liver cells in bile duct-ligated rats. Turk J Gastroenterol 2009; 20: 247-256.
25. Yang F, Gaudio E, Onori P, Wise P, Alpini G, Glaser S. Mechanisms of biliary damage. J Cell Death 2010; 3: 13-21.
26. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005; 39(4 Suppl 2): S90-S102.
27. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009; 30: 42-59.
28. Serviddio G, Pereda J, Pallardo FV, et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39: 711-720.
29. Schreck R, Ribor P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10: 2247-2258.
30. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206.
31. Kisseleva T, Brenner DA. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 2011; 25: 305-317.
32. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 1723-1739.
33. Bhattacharyya NK, Chatterjee U, Sarkar S, Kundu AK. A study of proliferative activity, angiogenesis and nuclear grading in renal cell carcinoma. Indian J Pathol Microbiol 2008; 511:17-21.
34. Demirbilek S, Akin M, Gurunluoglu K, et al. The NF-kappaB inhibitors attenuate hepatic injury in bile duct ligated rats. Pediatr Surg Int 2006; 22: 655-663.
35. Demirbilek S, Tas E, Gurunluoglu K, et al. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Pediatr Surg Int 2007; 23: 155-162.
36. Glaser SS, Onori P, Wise C, et al. Recent advances in the regulation of cholangiocyte proliferation and function during extrahepatic cholestasis. Dig Liver Dis 2010; 42: 245-252.